However, our study has the following limitations: (1) the associations between UGT expression in tumours and intratumoural androgen levels were not performed, (2) the limited number of events for clinical endpoints such as nodal status and metastasis and (3) the insufficient sample size to analyse simultaneously the impact of both UGT2B17 and UGT2B28 on disease characteristics and progression. The gene discussed is UGT2B28; the disease is neoplasm.